Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Acorda Therapeutics's accounts receivables for the quarter that ended in Dec. 2023 was $17.3 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Acorda Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 41.55.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Acorda Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-173.46.
Acorda Therapeutics Accounts Receivable Historical Data
The historical data trend for Acorda Therapeutics's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Acorda Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Acorda Therapeutics's accounts receivable are only considered to be worth 75% of book value:
Acorda Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Acorda Therapeutics Accounts Receivable Related Terms
Thank you for viewing the detailed overview of Acorda Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Acorda Therapeutics (Acorda Therapeutics) Business Description
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACORQ has been successfully added to your 